Human leukocyte antigen (HLA) system
|
|
- Neal Paul
- 5 years ago
- Views:
Transcription
1 Is HLA a determinant of prognosis or therapeutic response to cytokines, IFN and anti-ctla4 blocking antibodies in melanoma? Helen Gogas, M.D. Ass. Professor in Medical Oncology 1st Department of Medicine, University of Athens, GREECE New York, September 2011 XV Perspectives in Melanoma Human leukocyte antigen (HLA) system HLA l h 6 t i HLA complex on chromosome 6 contains over 200 genes More than 40 of which encode leukocyte antigens The HLA genes that are involved in the immune response fall into two classes I and II, which are structurally and functionally different 1
2 Human leukocyte antigen (HLA) system II Class I genes are expressed by most somatic cells, although the level of expression varies depending on the tissue Class II genes are normally expressed by a subgroup of immune cells that includes B cells, activated t T cells, macrophages, dendritic d cells, and thymic epithelial cells In the presence of interferon-γ, other types of cells can express class II HLA molecules Human leukocyte antigen (HLA) system III The function of both class I and class II molecules is the presentation of short, pathogen derived peptides to T-cells, a process that initiates the adaptive immune response 2
3 Abnormalities of genes linked to the HLA complex Narcolepsy Hemochromatosis Infections diseases (eg malaria) Autoimmune diseases Genetic studies have shown that persons who have certain HLA alleles have a higher risk of specific autoimmune diseases than persons without these alleles Cancer Autoimmune diseases HLA-B27 HLA-DQA1*301 HLA-DQB1*302 HLA-DQ8 HLA-DR3 HLA-DR4 HLA-DR4 HLA-B51 HLA-DR3 HLA-DR3 HLA-DR11 HLA-DR4 HLA-DR3 HLA-Cw6 Ankylosing spondylitis Diabetes mellitus type I Rheumatoid arthritis Behcet s syndrome SLE Graves Hashimoto Postpartum thyroiditis Sicca syndrome Psoriasis 3
4 HLA and melanoma Susceptibility (conflicting data have been reported on HLA association and melanoma) Prognosis (relationship to disease recurrence) Linkage with prediction of response to treatment Susceptibility 4
5 No of patients Ethnicity HLA Reference 91 US Alabama DR4 Cancer Res, Italian A9, B35, Tumori, 1988 Cw4 146 NAC A11 Cancer Res, NAC B5, B8, B14, B15 J Immunother Emphasis Tumor Immunol, 1995 J Immunother, Italian DQB1*0501 J Immunother, 1998 DQB1* Italian DQB1*0301 Tissue Antigens, , Spanish DR, DQ Acta Derm Venereol, 2002 Prognosis 5
6 No of patients Ethnicity HLA Reference 259 NAC DQB1*301 Cancer, NAC DRB1*1101 Annals of Surgical Oncology, NAC DRB1*1101 Proc ASCO, Italian DRB1*01, DQB1*050, B*13, B*44, DRB1* Australian HLA-A2, B7, B35, B60 Tissue Antigens, 2004 Peter Hersey, Personal Communication Prediction 6
7 146 patients receiving undergoing IL-2 based immunotherapy. Significantly higher frequency of A11 phenotype among responders (40.5%) than in the melanoma patient population (20.5%; p<0.01), which was even more obvious among patients responding to TIL therapy (47.5% versus 22.1%; p<0.05). Association between DR4 haplotype and decreased tolerance to IL-2 among the patients receiving TILs (p=0.01). Cancer Res, patients receiving immunotherapy with IFNalpha and IL-2. Two HLA alleles Cw7 (p=0.014) and A1 (p=0.19) were observed more frequently in responding gpatients 272 patients receiving IL-2 based treatment. A correlation was noted between HLA-DR3 and DR4 alleles and decreased tolerance to IL-2, whereas homozygosity for HLA-DR decreased the chance of response. Melanoma Res, 1994 J Immunother Emphasis Tumor Immunol,
8 82 patients treated with IL-2 based therapy. A statistically significant association between clinical response and the expression of HLA-DQ1 was observed (unadjusted p2=0.0017). HLA-DQ1 Was also independently associated with prolonged survival (p2=0.026). Ther Immunology, enrolled patients (294 vaccinated with allogeneic tumor vaccine and 259 observed). Among patients who matched two of the M5, the 97 vaccine treated patients had improved RFS compared with the 78 observation patients (5-year relapse-free survival, 83% vs 59%; p=0.0002). 0002) The major components of this effect were contributed by HLA-A2 and HLA-C3. Among those who were HLA-A2- positive and/or HLA-C3-positive, the 5-year RFS for vaccinated patients was 77%, compared with 64% for observation (p=0.004). This prospective analysis indicates a highly significant benefit of adjuvant therapy with Melacine among patients expressing two of the M5 class I antigens, validating a prior observation in stage IV disease. HLA-A2 and HLA- C3 contributed most to this effect. J Clin Oncol,
9 INF and HLA 51 patients treated with high dose IFN-α2b and 54 patients treated with low dose in protocol E1690 Among patients t in the HLA-A2 A2 positive subset, IFNα2b treatment had a negative impact on RFS (p=0.02) compared with the OBS arm Among patients in the HLA-A2 negative subset, the RFS survival curves were the same as those reported for the largest experience in Trials E1690, E1684 and E1694 The test for interaction between treatment and HLA-A2 status was marginally significant (p=0.06) Cancer, 2002 Molecular HLA typing (Gogas, 2010) No allele was associated with absence of recurrence in patients receiving adjuvant interferon with the exception of HLA-Cw 06, an allele correlated with psoriasis. HLA-Cw 06-positive patients have better relapse-free and overall survival. 9
10 Relapse Results No of patients % No Yes Deaths No Yes Median follow-up months 36.6 HLA-Cw Patients (%) Controls (%) No evidence Recurrence (%) Autoimmunity (%) (%) Cw* Cw* Cw* Cw*
11 Cw*06 Median RFS Range 95% CI P-value Negative Positive Median Range 95% CI P-value OS Negative Positive NRY NE RFS plot by HLA-A2 status Survival Functions Probability of 0,8 0,6 0,4 0,2 0,0 f Relapse Free Survival1,0 HLAAx02 negative positive positivecensored negativecensored 0,00 20,00 40,00 60,00 80,00 100,00 Months from Start of Treatment 120,00 11
12 OS plot by HLA-A2 status Survival Functions y of Overall Survival Probability 1,0 0,8 0,6 0,4 0,2 HLAAx02 negative positive 0,0 0,00 25,00 50,00 75,00 100,00 125,00 Months from Start of Treatment RFS plot by Cw6 status Survival Functions Probability of 0,8 0,6 0,4 0,2 0,0 f Relapse Free Survival1,0 HLACx06 negative positive positivecensored negativecensored positivecensored negativecensored 0,00 20,00 40,00 60,00 80,00 100,00 Months from Start of Treatment 120,00 12
13 OS plot by Cw6 status Survival Functions y of Overall Survival Probability 1,0 0,8 0,6 0,4 0,2 HLACx censored 1.00-censored 0,0 0,00 25,00 50,00 75,00 100,00 125,00 SURV Questions Raised Do Cw*06 positive patients have slower growing Do Cw 06 positive patients have slower growing melanomas irrespective of IFN therapy? (Prognostic rather than a predictive factor?) 13
14 Retrospective Validation (collaboration with Prof. Dirk Schadendorf, in 279 melanomas) E1695 (Prof. J. Kirkwood) Prospective E1697 E1609 A phase III, randomized, double-blind, multicenter study comparing monotherapy with ipilimumab or gp100 peptide vaccine and the combination in patients with previously treated, unresectable stage III or IV melanoma Study MDX O Day, ODay, S. (2010). "A phase III, randomized, double-blind, blind, multicenter study comparing monotherapy with ipilimumab or gp100 peptide vaccine and the combination in patients with previously treated, unresectable stage III or IV melanoma." ASCO Annual Meeting Abstracts J Clin Oncol 28:18s, 2010 (suppl; abstr 4) Hodi, F. S., O'Day, S. J. et al. (2010). "Improved Survival with Ipilimumab in Patients with Metastatic Melanoma." N Engl J Med. 14
15 MDX010-20: Patient Eligibility Inclusion Pre-treated stage III or IV melanoma HLA-A*0201 positive Pre-treated CNS metastases allowed Any LDH level Exclusion No autoimmune disease No prior therapy with anti-ctla-4 antibody No prior therapy with anti-cancer vaccine Ipilimumab and HLA Retrospective analysis of HLA subtype from 4 trials : Similar outcomes regardless of HLA-A*0201. Wolchok JD et al.,
16 Summary of phase II advanced melanoma trials used as data sources for pooled analysis and the comparator phase III study Study Population Treatment Regimen Reference CA /NC Pretreated t or Ipilimumab 3mg/kg (n=40) or 10mg/kg Schmidt et al 2009 T (phase II) untreated AM n=82 (n=42) Q3W x 4 then maintenance (Q12W) CA / NC T (phase II) CA / NC T (phase II) Pretreated AM N = 217 Pretreated AM N = 155 Ipilimumab 0.3 mg/kg (n=73), 3mg/kg (n=72) or 10 mg/kg (n=72) Q3W x 4 then maintenance (Q12w) Ipilimumab 10 mg/kg Q3W x 4 then maintenance (Q12W) Wolchok et al 2010 O Day et al CA / NC Pretreated or Ipilimumab 10mg/kg Q3W x 4 Weber et al 2009 T (phase II) untreated AM ±prophylactic budesonide (n =58) or N = 115 placebo (n=57) MDX / NC T (phase II) Pretreated AM n=676 (137 received ipilimumab alone) Ipilimumab 3 mg/kg Q3W x 4 ± gp100 vaccine, or vaccine only Hodi et al 2010 HLAA2*201 status and efficacy (survival, response, and disease control) across phase II trials versus the phase III study Ipilimumab Dose (study) HLA- A2*201 status (n) Median OS months 1-year Survival rate % 2-year Survival rate % Response BORR n (%) DCR N (%) 3mg/kg (CA /022) -(47) +(46) (4.3) 3 (6.5) 11 (23,4) 15 (32.6) 10 mg/kg (CA /008/007/022) -(176) +(116) (11.4) 9 (7.8) 51 (29.0) 33 (28.4) 0.3, 3 and 10 mg/kg (CA /008/007/022) -(266) +(187) (8.3) 12 (6.4) 68 (25.6) 52 (27.8) 3 mg/kg (MDX ) +(137) (10.9) 39 (28.5) 16
17 Conclusions HLA-A2 does not predict for outcome in melanoma patients treated with IFN, ipilimumab, IL-2 or GM-CSF. Presence of HLA-Cw*6 is related with better outcome in IFNtreated t patients. t Its role needs to be investigated in populations treated with other cytokines. 17
18 Thank you 18
A Case Study: Ipilimumab in Pre-treated Metastatic Melanoma
A Case Study: Ipilimumab in Pre-treated Metastatic Melanoma Tai-Tsang Chen, PhD Global Biometric Sciences, Bristol-Myers Squibb EFSPI Statistical Meeting on Evidence Synthesis Brussels, Belgium November
More informationMarshall T Bell Research Resident University of Colorado Grand Rounds Nov. 21, 2011
Marshall T Bell Research Resident University of Colorado Grand Rounds Nov. 21, 2011 Most common form of cancer in adults ages 25-29 3-5% of skin cancers but 65-75% of deaths Most common metastasis to small
More informationName of Policy: Yervoy (Ipilimumab)
Name of Policy: Yervoy (Ipilimumab) Policy #: 335 Latest Review Date: October 2013 Category: Pharmacology Policy Grade: A Background/Definitions: As a general rule, benefits are payable under Blue Cross
More informationUpdate on Immunotherapy in Advanced Melanoma. Ragini Kudchadkar, MD Assistant Professor Winship Cancer Institute Emory University Sea Island 2017
Update on Immunotherapy in Advanced Melanoma Ragini Kudchadkar, MD Assistant Professor Winship Cancer Institute Emory University Sea Island 2017 1 Outline Adjuvant Therapy Combination Immunotherapy Single
More informationIpilimumab ASCO Data Review and Discussion Webcast. Monday, June 2, 2008
Ipilimumab ASCO Data Review and Discussion Webcast Monday, June 2, 2008 Slide 2 Forward Looking Statements Except for historical information, the matters contained in this slide presentation may constitute
More informationImmunotherapy for the Treatment of Melanoma. Marlana Orloff, MD Thomas Jefferson University Hospital
Immunotherapy for the Treatment of Melanoma Marlana Orloff, MD Thomas Jefferson University Hospital Disclosures Immunocore and Castle Biosciences, Consulting Fees I will be discussing non-fda approved
More informationEndogenous and Exogenous Vaccination in the Context of Immunologic Checkpoint Blockade
Endogenous and Exogenous Vaccination in the Context of Immunologic Checkpoint Blockade Jedd Wolchok Ludwig Center for Cancer Immunotherapy Memorial Sloan-Kettering Cancer Center MEMORIAL SLOAN- KETTERING
More informationImmunotherapy, an exciting era!!
Immunotherapy, an exciting era!! Yousef Zakharia MD University of Iowa and Holden Comprehensive Cancer Center Alliance Meeting, Chicago November 2016 Presentation Objectives l General approach to immunotherapy
More informationImmunotherapy in the Adjuvant Setting for Melanoma: What You Need to Know
Immunotherapy in the Adjuvant Setting for Melanoma: What You Need to Know Jeffrey Weber, MD, PhD Laura and Isaac Perlmutter Cancer Center NYU Langone Medical Center New York, New York What Is the Current
More informationImproving Immunotherapy for Melanoma
Improving Immunotherapy for Melanoma David McDermott, MD Beth Israel Deaconess Medical Center Dana Farber/ Harvard Cancer Center Harvard Medical School Immunotherapy Improvement Model All patients All
More informationAdjuvant Therapy of High Risk Melanoma
Adjuvant Therapy of High Risk Melanoma William Sharfman, MD, FACP Associate Professor of Oncology and Dermatology Johns Hopkins University School of Medicine July 5, 2012 Adjuvant options for Stage IIB/C
More informationCurrent Trends in Melanoma Theresa Medina, MD UCD Cutaneous Oncology
Current Trends in Melanoma Theresa Medina, MD UCD Cutaneous Oncology Overview Melanoma incidence and prevention Approach to surgical management of early melanoma Landscape of Advanced Melanoma Therapy
More informationMelanoma: Immune checkpoints
ESMO Preceptorship Programme Immuno-Oncology Siena, July 04-05, 2016 Melanoma: Immune checkpoints Michele Maio Medical Oncology and Immunotherapy-Department of Oncology University Hospital of Siena, Istituto
More informationImmunotherapy versus targeted treatments in metastatic renal cell carcinoma: The return game?
Immunotherapy versus targeted treatments in metastatic renal cell carcinoma: The return game? Sylvie NEGRIER MD, PhD Centre Léon Bérard, Lyon Université Lyon I IMMUNOTHERAPY: A LONG AND WIDING ROAD! WHERE
More informationClinical Perspectives Highlights from the Perspectives in Melanoma XII Conference Scheveningen/The Hague, the Netherlands, October 2-4, 2008
ADJUVANT THERAPY Clinical Perspectives Highlights from the Perspectives in Melanoma XII Conference Scheveningen/The Hague, the Netherlands, October 2-4, 2008 Updated analysis and discussion of current
More informationMetastasectomy for Melanoma What s the Evidence and When Do We Stop?
Metastasectomy for Melanoma What s the Evidence and When Do We Stop? Vernon K. Sondak, M D Chair, Moffitt Cancer Center Tampa, Florida Focus on Melanoma London, UK October 15, 2013 Disclosures Dr. Sondak
More informationIII Sessione I risultati clinici
10,30-13,15 III Sessione I risultati clinici Moderatori: Michele Maio - Valter Torri 10,30-10,45 Melanoma: anti CTLA-4 Vanna Chiarion Sileni Vanna Chiarion Sileni IOV-IRCCS,Padova Vanna.chiarion@ioveneto.it
More informationAutoimmune diseases. Autoimmune diseases. Autoantibodies. Autoimmune diseases relatively common
Autoimmune diseases Fundamental abnormality: the adaptive immune system is triggered by self antigens to initiate a sustained immune response against self molecules that results in tissue injury Specificity
More informationClinical: Ipilimumab (MDX-010) Update and Next Steps
Clinical: Ipilimumab (MDX-010) Update and Next Steps Geoffrey M. Nichol, M.D., M.B.A. Senior Vice President, Product Development Medarex, Inc. R&D Day December 9, 2005 Ipilimumab: New Class of Cancer Therapy
More informationNational Horizon Scanning Centre. Ipilimumab (MDX-010) for unresectable stage III or IV metastatic melanoma - first or second line treatment
Ipilimumab (MDX-010) for unresectable stage III or IV metastatic melanoma - first or second line treatment April 2008 This technology summary is based on information available at the time of research and
More informationSignificance of the MHC
CHAPTER 7 Major Histocompatibility Complex (MHC) What is is MHC? HLA H-2 Minor histocompatibility antigens Peter Gorer & George Sneell (1940) Significance of the MHC role in immune response role in organ
More informationGlioblastoma and CNS tumors
Glioblastoma and CNS tumors PRECEPTORSHIP PROGRAMME IMMUNO-ONCOLOGY Amsterdam, 27 May 2017 Patrick Roth Department of Neurology and Brain Tumor Center University Hospital Zurich Challenges in immunooncology
More informationRenal Cell Carcinoma: Systemic Therapy Progress and Promise
Renal Cell Carcinoma: Systemic Therapy Progress and Promise Michael B. Atkins, M.D. Deputy Director, Lombardi Comprehensive Cancer Ctr Georgetown University Medical Center Everolimus Rini, Campbell, Escudier.
More informationClinical Perspectives Highlights from the Perspectives in Melanoma XII Conference Scheveningen/The Hague, the Netherlands, October 2-4, 2008
Clinical Perspectives Highlights from the Perspectives in Melanoma XII Conference Scheveningen/The Hague, the Netherlands, October 2-4, 2008 REPORTS ON IMPORTANT ONGOING CLINICAL TRIALS CTLA-4 directed
More informationWhat we learned from immunotherapy in the past years
What we learned from immunotherapy in the past years Paolo A. Ascierto, MD Unit Melanoma, Cancer Immunotherapy and Innovative Therapies Istituto Nazionale Tumori Fondazione G. Pascale, Napoli, Italy Disclosure
More informationHLA and antigen presentation. Department of Immunology Charles University, 2nd Medical School University Hospital Motol
HLA and antigen presentation Department of Immunology Charles University, 2nd Medical School University Hospital Motol MHC in adaptive immunity Characteristics Specificity Innate For structures shared
More informationThe Challenge of Bringing Forward New Agents for Systemic Therapy of Melanoma
The Challenge of Bringing Forward New Agents for Systemic Therapy of Melanoma John M. Kirkwood, MD Director, Melanoma and Skin Cancer Program University of Pittsburgh Cancer Institute Professor & Vice
More informationCancer Progress. The State of Play in Immuno-Oncology
Cancer Progress The State of Play in Immuno-Oncology Axel Hoos, MD, PhD VP, Oncology R&D, Glaxo Smith Kline Co-Director, Cancer Immunotherapy Consortium Key Drivers in Immuno-Oncology Science Methods Combinations
More informationImmune Checkpoint Inhibitors: The New Breakout Stars in Cancer Treatment
Immune Checkpoint Inhibitors: The New Breakout Stars in Cancer Treatment 1 Introductions Peter Langecker, MD, PhD Executive Medical Director, Global Oncology Clinipace Worldwide Mark Shapiro Vice President
More informationGlioblastoma and CNS tumors
Glioblastoma and CNS tumors PRECEPTORSHIP PROGRAMME IMMUNO-ONCOLOGY Amsterdam, 1 October 2016 Patrick Roth Department of Neurology and Brain Tumor Center University Hospital Zurich Immunology in the CNS
More informationImmunotherapy in Unresectable or Metastatic Melanoma: Where Do We Stand? Sanjiv S. Agarwala, MD St. Luke s Cancer Center Bethlehem, Pennsylvania
Immunotherapy in Unresectable or Metastatic Melanoma: Where Do We Stand? Sanjiv S. Agarwala, MD St. Luke s Cancer Center Bethlehem, Pennsylvania Overview Background Immunotherapy clinical decision questions
More informationCancer Registry Report. Cancer Focus: Melanoma
Cancer Registry Report Cancer Focus: Melanoma In 2005, nearly 60,000 patients were diagnosed with melanoma, resulting in about 7800 deaths Fortunately, melanoma is often diagnosed in an early stage when
More informationProstate Cancer 2009 MDV Anti-Angiogenesis. Anti-androgen Radiotherapy Surgery Androgen Deprivation Therapy. Docetaxel/Epothilone
Prostate Cancer 2009 Anti-Angiogenesis MDV 3100 Anti-androgen Radiotherapy Surgery Androgen Deprivation Therapy Docetaxel/Epothilone Abiraterone DC therapy Bisphosphonates Denosumab Secondary Hormonal
More informationCytokines: Interferons, Interleukins and Beyond. Michael B. Atkins, MD Georgetown-Lombardi Comprehensive Cancer Center
Cytokines: Interferons, Interleukins and Beyond Michael B. Atkins, MD Georgetown-Lombardi Comprehensive Cancer Center Disclosures Advisory Boards: Bristol-Myers Squibb,Amgen, Novartis, Alkermes, Infinity,
More informationImmunotherapy for Melanoma. Caroline Robert, MD, PhD Gustave Roussy and Université Paris Sud Villejuif, France
Immunotherapy for Melanoma Caroline Robert, MD, PhD Gustave Roussy and Université Paris Sud Villejuif, France Overall Survival for Metastatic Melanoma Proportion Alive 1.0 0.8 0.6 0.4 0.2 Survival data
More informationPTAC meeting held on 5 & 6 May (minutes for web publishing)
PTAC meeting held on 5 & 6 May 2016 (minutes for web publishing) PTAC minutes are published in accordance with the Terms of Reference for the Pharmacology and Therapeutics Advisory Committee (PTAC) and
More informationNew Frontiers in Metastatic Melanoma: A Closer Look at the Role of Immunotherapy
New Frontiers in Metastatic Melanoma: A Closer Look at the Role of Immunotherapy Philip Friedlander MD PhD Director of Melanoma Medical Oncology Program Assistant Professor Division of Hematology Oncology
More informationNew paradigms for treating metastatic melanoma
New paradigms for treating metastatic melanoma Paul B. Chapman, MD Melanoma Clinical Director Melanoma and Immunotherapeutics Service Memorial Sloan Kettering Cancer Center, New York 20 th Century Overall
More informationManagement of Brain Metastases Sanjiv S. Agarwala, MD
Management of Brain Metastases Sanjiv S. Agarwala, MD Professor of Medicine Temple University School of Medicine Chief, Oncology & Hematology St. Luke s Cancer Center, Bethlehem, PA, USA Incidence (US):
More informationReview of immunotherapy in melanoma
Review of immunotherapy in melanoma Surein Arulananda, 1,2,3 Elizabeth Blackley, 1 Jonathan Cebon 1,2,3 1. Department of Medical Oncology, Austin Health, Heidelberg, Victoria, Australia. 2. Cancer Immunobiology
More informationHLA AND DISEASE. M. Toungouz Nevessignsky. Erasme Hospital Brussels, Belgium EFI - ULM 2009
HLA AND DISEASE M. Toungouz Nevessignsky Université Libre de Bruxelles (ULB) Erasme Hospital Brussels, Belgium HLA and disease: pioneer studies 1972: Falcuk et al HLA B8 and coeliac disease 1972: Russell
More informationHLA and antigen presentation. Department of Immunology Charles University, 2nd Medical School University Hospital Motol
HLA and antigen presentation Department of Immunology Charles University, 2nd Medical School University Hospital Motol MHC in adaptive immunity Characteristics Specificity Innate For structures shared
More informationMelanoma: Therapeutic Progress and the Improvements Continue
Melanoma: Therapeutic Progress and the Improvements Continue David W. Ollila, MD Professor of Surgery Jesse and James Millis Professor of Melanoma Research May 20, 2016 Disclosures: NONE Outline 2016 Therapeutic
More informationIMMUNOTHERAPY IN THE TREATMENT OF CERVIX CANCER. Linda Mileshkin, Medical Oncologist Peter MacCallum Cancer Centre, Melbourne Australia
IMMUNOTHERAPY IN THE TREATMENT OF CERVIX CANCER Linda Mileshkin, Medical Oncologist Peter MacCallum Cancer Centre, Melbourne Australia Distinguishing self from non-self T cells trained in the thymus as
More informationCheckpoint regulators a new class of cancer immunotherapeutics. Dr Oliver Klein Medical Oncologist ONJCC Austin Health
Checkpoint regulators a new class of cancer immunotherapeutics Dr Oliver Klein Medical Oncologist ONJCC Austin Health Cancer...Immunology matters Anti-tumour immune response The participants Dendritc cells
More informationIMMUNOTARGET THERAPY: ASPETTI GENERALI
IMMUNOTARGET THERAPY: ASPETTI GENERALI Alessandro Minisini Dipartimento di Oncologia Azienda Ospedaliero Universitaria Udine Verona, 19 settembre 2015 HALLMARKS OF CANCER Douglas Hanahan, Robert A. Weinberg,
More informationIMMUNOTHERAPY IN THE TREATMENT OF CERVIX CANCER
Gynecologic Cancer InterGroup Cervix Cancer Research Network IMMUNOTHERAPY IN THE TREATMENT OF CERVIX CANCER Linda Mileshkin, Medical Oncologist Peter MacCallum Cancer Centre, Melbourne Australia Cervix
More informationASCO 2010 Update. Advanced Non Small Cell Lung Cancer 7/13/2010. Background. Background. ALK fusion protein. ALK-positive NSCLC
The American Society of Clinical Oncology (ASCO) 2010 Annual Meeting, which returned to Chicago this year, held June 4-8. ASCO 2010 Update Advancing quality through innovation Suphat Subongkot, Pharm.D.,BCPS,
More informationDeveloping Novel Immunotherapeutic Cancer Treatments for Clinical Use
Developing Novel Immunotherapeutic Cancer Treatments for Clinical Use Oncology for Scientists March 8 th, 2016 Jason Muhitch, PhD Assistant Professor Department of Urology Email: jason.muhitch@roswellpark.org
More informationMELANOMA METASTASICO: NUEVAS COMBINACIONES. Dr Ana Arance MD PhD Oncología Médica Hospital Clínic Barcelona
MELANOMA METASTASICO: NUEVAS COMBINACIONES Dr Ana Arance MD PhD Oncología Médica Hospital Clínic Barcelona Summary of OS accross clinical trials in patients with metastatic melanoma Ugurel et al. Eur J
More informationA Prospective Phase II Trial of Deintensified Chemoradiation Therapy for Low Risk HPV Associated Oropharyngeal Squamous Cell Carcinoma
A Prospective Phase II Trial of Deintensified Chemoradiation Therapy for Low Risk HPV Associated Oropharyngeal Squamous Cell Carcinoma B. S. Chera 1, R. J. Amdur 2, J. E. Tepper 3, B. Qaqish 4, R. Green
More information6/7/16. Melanoma. Updates on immune checkpoint therapies. Molecularly targeted therapies. FDA approval for talimogene laherparepvec (T- VEC)
Melanoma John A Thompson MD July 17, 2016 Featuring: Updates on immune checkpoint therapies Molecularly targeted therapies FDA approval for talimogene laherparepvec (T- VEC) 1 Mechanism of ac-on of Ipilimumab
More informationPriming the Immune System to Kill Cancer and Reverse Tolerance. Dr. Diwakar Davar Assistant Professor, Melanoma and Phase I Therapeutics
Priming the Immune System to Kill Cancer and Reverse Tolerance Dr. Diwakar Davar Assistant Professor, Melanoma and Phase I Therapeutics Learning Objectives Describe the role of the immune system in cancer
More informationMelanoma Vaccines. Description
Subject: Melanoma Vaccines Page: 1 of 8 Last Review Status/Date: September 2014 Melanoma Vaccines Description Tumor vaccines are a type of active immunotherapy that attempts to stimulate the patient s
More informationMelanoma: From Chemotherapy to Targeted Therapy and Immunotherapy. What every patient needs to know. James Larkin
Melanoma: From Chemotherapy to Targeted Therapy and Immunotherapy What every patient needs to know James Larkin Melanoma Therapy 1846-2017 Surgery 1846 Cytotoxic Chemotherapy 1946 Checkpoint Inhibitors
More informationHighlights STOMACH CANCER
UPDATES and NEWS from the Gastrointestinal Cancers Symposium in San Francisco Roma, 10-11 Febbraio 2017 Highlights STOMACH CANCER Lorenzo Fornaro, MD Unit of Medical Oncology 2 Azienda Ospedaliero-Universitaria
More informationImmunotherapies in melanoma: regulatory perspective. Jorge Camarero (AEMPS)
Immunotherapies in melanoma: regulatory perspective Jorge Camarero (AEMPS) Challenges for the approval of anti-cancer immunotherapeutic drugs EMA-CDDF joint meeting, London 4-5 February 2016 disclaimers
More informationThe Immunotherapy of Oncology
The Immunotherapy of Oncology The 30-year Overnight Success Story M Avery, BIOtech Now 2014 Disclosures: Geoffrey R. Weiss, M.D. None The History A. Chekov: It has long been noted that the growth of malignant
More informationWhat is Autoimmunity?
Autoimmunity What is Autoimmunity? Robert Beatty MCB150 Autoimmunity is an immune response to self antigens that results in disease. The immune response to self is a result of a breakdown in immune tolerance.
More informationWhat is Autoimmunity?
Autoimmunity What is Autoimmunity? Robert Beatty MCB150 Autoimmunity is an immune response to self antigens that results in disease. The immune response to self is a result of a breakdown in immune tolerance.
More informationNew Systemic Therapies in Advanced Melanoma
New Systemic Therapies in Advanced Melanoma Sanjay Rao, MD FRCPC Medical Oncologist (BCCA-CSI) Clinical Assistant Professor, UBC Faculty of Medicine SON Fall Update October 22, 2016 Disclosures Equity
More informationWho is the Ideal Candidate for PEG Intron?
Who is the Ideal Candidate for PEG Intron? Sanjiv S. Agarwala, MD Chief, Oncology & Hematology St. Luke s Cancer Center Professor, Temple University School of Medicine Philadelphia, PA, USA Overview Introduction
More informationImmunotherapy for dmmr metastatic colorectal cancer. Prof.dr. Kees Punt Dept. Medical Oncology AUMC
Immunotherapy for dmmr metastatic colorectal cancer Prof.dr. Kees Punt Dept. Medical Oncology AUMC Active specific immunotherapy (ASI) in stage II-III colon cancer Vaccination with autologous tumor + BCG
More informationNivolumab: esperienze italiane nel carcinoma polmonare avanzato
NSCLC avanzato: quali novità nel 2018? Negrar, 30 Ottobre 2018 Nivolumab: esperienze italiane nel carcinoma polmonare avanzato Francesco Grossi UOC Oncologia Medica Fondazione IRCCS Ca Granda Ospedale
More informationStaging of Type 1 Diabetes: Clinical Implications. April Deborah Hefty, MN, RN, CDE.
Staging of Type 1 Diabetes: TT Clinical Implications April 2016 Deborah Hefty, MN, RN, CDE dhefty@benaroyaresearch.org BRI s major contributions to type 1 diabetes research Identified type 1 diabetes susceptibility
More informationSignificance of the MHC
CHAPTER 8 Major Histocompatibility Complex (MHC) What is is MHC? HLA H-2 Minor histocompatibility antigens Peter Gorer & George Sneell (1940) Significance of the MHC role in immune response role in organ
More informationSociety for Immunotherapy of Cancer (SITC) Immunotherapy for the Treatment of Brain Metastases
Society for Immunotherapy of Cancer (SITC) Immunotherapy for the Treatment of Brain Metastases Geoffrey T. Gibney, MD Georgetown-Lombardi Comprehensive Cancer Center Medstar-Georgetown University Hospital
More informationThe following protocol information is provided solely to describe how the authors conducted
The following protocol information is provided solely to describe how the authors conducted the research underlying the published report associated with the following article: Phase III Trial of Combined
More informationNuovi approcci immunoterapici nel trattamento del Melanoma: Background immunologico.
Nuovi approcci immunoterapici nel trattamento del Melanoma: Background immunologico. Andrea Anichini Human Tumors Immunobiology Unit Dept. of Experimental Oncology and Molecular Medicine Immune checkpoint
More informationCDC Recommendations for Skin Cancer Prevention. Systemic Therapy for Melanoma. Melanoma Incidence by Age and Gender: U.S.
Systemic Therapy for Melanoma Adil Daud M.D. UCSF 0.016 0.016 1:74 1:74 Lifetime Risk Risk Lifetime 0.014 0.014 0.012 0.012 1:100 1:100 0.010 0.010 1:150 1:150 0.008 0.008 0.006 0.006 1:250 1:250 0.004
More informationThe Current Status of Immune Checkpoint Inhibitors: Arvin Yang, MD PhD Oncology Global Clinical Research Bristol-Myers Squibb
The Current Status of Immune Checkpoint Inhibitors: A Global Overview of the Field Arvin Yang, MD PhD Oncology Global Clinical Research Bristol-Myers Squibb Immune Checkpoint Inhibitors Conference, March
More informationImmunotherapy for the Treatment of Cancer
Immunotherapy for the Treatment of Cancer Jason Muhitch, PhD Assistant Professor Department of Urology Department of Immunology Roswell Park Comprehensive Cancer Center Oncology for Scientists March 15,
More informationTreatment and management of advanced melanoma: Paul B. Chapman, MD Melanoma Clinical Director, Melanoma and Immunotherapeutics Service MSKCC
Treatment and management of advanced melanoma: 2018 Paul B. Chapman, MD Melanoma Clinical Director, Melanoma and Immunotherapeutics Service MSKCC Disclosure Paul B. Chapman, MD Nothing to disclose. Off
More informationPatient Consult Report
Patient Consult Report Clinical History Currently 36 years old History of firstborn son now about 5 years old followed by secondary recurrent pregnancy loss with 9 losses (all between 6 and 11 weeks) over
More informationCheckMate 012: Safety and Efficacy of First Line Nivolumab and Ipilimumab in Advanced Non-Small Cell Lung Cancer
CheckMate 12: Safety and Efficacy of First Line Nivolumab and Ipilimumab in Advanced Non-Small Cell Lung Cancer Abstract 31 Hellmann MD, Gettinger SN, Goldman J, Brahmer J, Borghaei H, Chow LQ, Ready NE,
More informationImmunoterapia e melanoma maligno metastatico: siamo partiti da li. Vanna Chiarion Sileni Istituto Oncologico Veneto
Immunoterapia e melanoma maligno metastatico: siamo partiti da li Vanna Chiarion Sileni Istituto Oncologico Veneto Vanna.chiarion@iov.veneto.it Metastatic Melanoma Available Treatment: 197 217 Zelboraf
More informationKombination von Checkpointinhibitoren beim malignen Melanom
Kombination von Checkpointinhibitoren beim malignen Melanom Dirk Jäger Medizinische Onkologie Nationales Centrum für Tumorerkrankungen Universitätsklinikum Heidelberg Ipilimumab beim metastasierten Melanom
More informationAdverse effects of Immunotherapy. Asha Nayak M.D
Adverse effects of Immunotherapy Asha Nayak M.D None Financial Disclosures Objectives Understand intensity of the AEs. Understanding unique side-effects. Develop effective monitoring and management guidelines.
More informationImmunological Tolerance
Immunological Tolerance Introduction Definition: Unresponsiveness to an antigen that is induced by exposure to that antigen Tolerogen = tolerogenic antigen = antigen that induces tolerance Important for
More informationUniversity of California Los Angeles, Los Angeles, CA; 2. Department of Dermatology, University of Kiel, Kiel, Germany;
Final Efficacy Results of A3671009, a Phase III Study of Tremelimumab vs Chemotherapy (Dacarbazine or Temozolomide) in First-line Patients With Unresectable Melanoma Antoni Ribas, 1 Axel Hauschild, 2 Richard
More informationNew Therapeutic Approaches to Malignant Melanoma
2018 Master Class for Oncologists New Therapeutic Approaches to Malignant Melanoma F. Stephen Hodi, M.D. Dana-Farber Cancer Institute, Boston, MA Disclosure I have nothing to disclose. Off Label/Investigational
More informationOverview: Immunotherapy in CNS Metastases
Overview: Immunotherapy in CNS Metastases Manmeet Ahluwalia, MD, FACP Miller Family Endowed Chair in Neuro-Oncology Director Brain Metastasis Research Program Cleveland Clinic Disclosures Consultant- Monteris
More informationImmunotherapy for Genitourinary Cancers
Immunotherapy for Genitourinary Cancers Susan F. Slovin, MD, PhD Genitourinary Oncology Service Sidney Kimmel Center for Prostate and Urologic Cancers Memorial Sloan Kettering Cancer Center New York, New
More informationBrain mets under I.O.
Brain mets under I.O. Bernard Escudier Gustave Roussy, Villejuif, France Disclosure Honorarium received from BMS, Novartis, Pfizer, Bayer, Roche, Exelixis, Ipsen, Eisai, Calithera Travel Grant from BMS,
More informationImmunotherapy of Melanoma Sanjiv S. Agarwala, MD
Immunotherapy of Melanoma Sanjiv S. Agarwala, MD Professor of Medicine Temple University School of Medicine Chief, Oncology & Hematology St. Luke s Cancer Center, Bethlehem, PA Overview Metastatic Melanoma
More informationThe Really Important Questions Current Immunotherapy Trials are Not Answering
The Really Important Questions Current Immunotherapy Trials are Not Answering David McDermott, MD Beth Israel Deaconess Medical Center Dana Farber/Harvard Cancer Center Harvard Medical School PD-1 Pathway
More informationAdvances in Cancer Immunotherapy for Solid Tumors Expert Perspectives on The New Data Sunday, June 5, 2016
Advances in Cancer Immunotherapy for Solid Tumors Expert Perspectives on The New Data Sunday, June 5, 2016 Supported by an independent educational grant from AstraZeneca Not an official event of the 2016
More informationMHC class I MHC class II Structure of MHC antigens:
MHC class I MHC class II Structure of MHC antigens: MHC class I antigens consist of a transmembrane heavy chain (α chain) that is non-covalently associated with β2- microglobulin. Membrane proximal domain
More informationImmunotherapy for Breast Cancer. Aurelio B. Castrellon Medical Oncology Memorial Healthcare System
Immunotherapy for Breast Cancer Aurelio B. Castrellon Medical Oncology Memorial Healthcare System Conflicts Research support : Cascadian therapeutics, Puma biotechnology, Odonate therapeutics, Pfizer,
More informationTargeted/Immunotherapy & Molecular Profiling State-of-the-art in Cancer Care
Targeted/Immunotherapy & Molecular Profiling State-of-the-art in Cancer Care Manmeet Ahluwalia, MD, FACP Miller Family Endowed Chair in Neuro-Oncology Director Brain Metastasis Research Program Cleveland
More informationBreast Cancer Immunotherapy. Leisha A. Emens, MD PhD Johns Hopkins University Bloomberg Kimmel Institute for Cancer Immunotherapy
Breast Cancer Immunotherapy Leisha A. Emens, MD PhD Johns Hopkins University Bloomberg Kimmel Institute for Cancer Immunotherapy Conflict of Interest I have the following financial relationships to disclose:
More informationAppendices. Appendix A Search terms
Appendices Appendix A Search terms Database Search terms Medline 1. Ipilimumab; 2. MDX-010; 3. MDX-101; 4. Yervoy; 5. BMS-734016; 6. Nivolumab; 7. ONO-4538; 8. BMS-936558; 9. MDX-1106; 10. Opdivo; 11.
More informationMultigene Testing in NCCN Breast Cancer Treatment Guidelines, v1.2011
Multigene Testing in NCCN Breast Cancer Treatment Guidelines, v1.2011 Robert W. Carlson, M.D. Professor of Medicine Stanford University Chair, NCCN Breast Cancer Treatment Guidelines Panel Selection of
More informationpresentation session & clinical Keith T. Flaherty, M.D. Abramson Cancer Center of the University of Pennsylvania
Melanoma: highlights from the oral presentation session & clinical science symposium at ASCO 2009 Keith T. Flaherty, M.D. Abramson Cancer Center of the University of Pennsylvania Abstracts to be discussed
More informationIdera Pharmaceuticals
Idera Pharmaceuticals ILLUMINATE-204 Clinical Data Update December 2018 Forward Looking Statements and Other Important Cautions This presentation contains forward-looking statements within the meaning
More informationReleasing the Brakes on Tumor Immunity: Immune Checkpoint Blockade Strategies
Releasing the Brakes on Tumor Immunity: Immune Checkpoint Blockade Strategies Jason Muhitch, PhD MIR 509 October 1 st, 2014 Email: jason.muhitch@roswellpark.org 0 Holy Grail of Tumor Immunity Exquisite
More informationBlack is the New Black or How I learned to stop worrying and love melanoma (with apologies to Dr. Strangelove)
Black is the New Black or How I learned to stop worrying and love melanoma (with apologies to Dr. Strangelove) Provincial Cancer Care Conference 2018 Ralph P.W. Wong MD FRCPC St Boniface Site Director
More informationContemporary Chemotherapy-Based Strategies for First-Line Metastatic Breast Cancer
Contemporary Chemotherapy-Based Strategies for First-Line Metastatic Breast Cancer Hope S. Rugo, MD Professor of Medicine Director, Breast Oncology and Clinical Trials Education University of California
More informationCONTRACTING ORGANIZATION: Memorial Sloan-Kettering Cancer Center New York, NY 10065
Award Number: W81XWH-10-1-0699 TITLE: Randomized Phase II Trial of Adjuvant WT-1 Analog Peptide Vaccine in Patients with Malignant Pleural Mesothelioma after Completion of Multimodality Therapy PRINCIPAL
More informationImmunotherapy for Melanoma. Michael Postow, MD Melanoma and Immunotherapeutics Service Memorial Sloan Kettering Cancer Center
Immunotherapy for Melanoma Michael Postow, MD Melanoma and Immunotherapeutics Service Memorial Sloan Kettering Cancer Center Conflicts of Interest Bristol-Myers Squibb: -Research support -Participated
More information